Abstract:Since α–secretase cleaves within the Aβ peptide domain, its activation may even have the double advantage of not only precluding the neurotoxic Aβ peptide formation but also generating the putatively neuroprotective sAPP–α. Thus, it would appear highly advantageous to shift APP cleavage from the amyloidogenic β–secretase to the non–amyloidogenic α–secretase cleavage. Indeed, we have recently shown that green tea polyphenol (–)–epigallocatechin–3–gallate (EGCG) exerts a beneficial role on reducing brain Aβ levels, resulting in mitigation of cerebral amyloidosis in a mouse model of Alzheimer's disease (AD). EGCG seems to accomplish this by modulating amyloid precursor protein (APP) processing, resulting in enhanced cleavage of the α–C–terminal fragment (α–CTF) of APP and corresponding elevation of the N–terminal APP product, soluble APP–α (sAPP–α). These beneficial effects were associated with increased α–secretase cleavage activity, but no significant alteration in β– or γ–secretase activities. To gain insight into the molecular mechanism whereby EGCG modulates APP processing, we evaluated the involvement of three candidate α–secretase enzymes, α–disintegrin–and–metalloprotease (ADAM) 9, 10, or 17, in EGCG–induced non–amyloidogenic APP metabolism. Results show that EGCG treatment of N2a cells stably transfected with “Swedish” mutant human APP (SweAPP N2a cells) leads to markedly elevated active (∼60 kDa mature form) ADAM10 protein. Elevation of active ADAM10 significantly correlated with increased α–CTF cleavage, and elevated sAPP–α in vitro and in vivo. To definitively test the contribution of ADAM10 to non–amyloidogenic APP metabolism, small interfering RNA knock–down of ADAM9, 10, or 17 mRNA was employed. Results show that ADAM10 (but not ADAM9 or 17) is critical for EGCG–mediated α–secretase cleavage activity. In summary, ADAM10 activation is necessary for EGCG promotion of non–amyloidogenic (α–secretase cleavage) APP processing. Thus, ADAM10 represents an important pharmacotherapeutic target for the treatment of cerebral amyloidosis in AD.

ADAM9 inhibition increases membrane activity of ADAM10 and controls α-secretase processing of amyloid precursor protein

Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer’s Disease Treatment

The Role of ADAM10 in Alzheimer’s Disease

Regulation of Alpha-Secretase ADAM10 In vitro and In vivo: Genetic, Epigenetic, and Protein-Based Mechanisms

ADAM10 Activation is Required for Green Tea (–)-Epigallocatechin-3-gallate-induced Α-Secretase Cleavage of Amyloid Precursor Protein

Characterizing the transmembrane domains of ADAM10 and BACE1 and the impact of membrane composition

P4–267: ADAM10 Activation is Required for Green Tea EGCG–induced Alpha–secretase Cleavage of Amyloid Precursor Protein

Apparent Reduction of ADAM10 in Scrapie-Infected Cultured Cells and in the Brains of Scrapie-Infected Rodents

ADAM30 Downregulates APP-Linked Defects Through Cathepsin D Activation in Alzheimer's Disease

ADAM10- and γ-secretase-dependent cleavage of the transmembrane protein PTPRT attenuates neurodegeneration in the mouse model of Alzheimer's disease

Therapeutic Approaches to Alzheimer'S Disease Through Stimulating of Non-Amyloidogenic Processing of Amyloid Precursor Protein

MicroRNA-144 is Regulated by Activator Protein-1 (AP-1) and Decreases Expression of Alzheimer Disease-related A Disintegrin and Metalloprotease 10 (ADAM10)

ADAM10 and ADAM17 are degraded by lysosomal pathway via asparagine endopeptidase

ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker

Tat-Hafgf(14-154) Upregulates Adam10 To Attenuate The Alzheimer Phenotype Of App/Ps1 Mice Through The Pi3k-Creb-Ire1 Alpha/Xbp1 Pathway

Peptides of presenilin-1 bind the amyloid precursor protein ectodomain and offer a novel and specific therapeutic approach to reduce ß-amyloid in Alzheimer's disease

The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3

Tat-haFGF14-154 Upregulates ADAM10 to Attenuate the Alzheimer Phenotype of APP/PS1 Mice through the PI3K-CREB-IRE1α/XBP1 Pathway

Tat-haFGF 14–154 Upregulates ADAM10 to Attenuate the Alzheimer Phenotype of APP/PS1 Mice Through the PI3K-CREB-IRE1α/XBP1 Pathway

The BACE1-Specific DNA Aptamer A1 Rescues Amyloid-β Pathology and Behavioral Deficits in a Mouse Model of Alzheimer's Disease

Macromolecular and small-molecule modulation of intracellular Aβ42 aggregation and associated toxicity.